Janus Henderson Group PLC reduced its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 0.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,009,028 shares of the company’s stock after selling 6,210 shares during the quarter. Janus Henderson Group PLC’s holdings in Alkermes were worth $73,310,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALKS. Meeder Asset Management Inc. grew its holdings in shares of Alkermes by 155.3% during the 4th quarter. Meeder Asset Management Inc. now owns 1,810 shares of the company’s stock worth $53,000 after purchasing an additional 1,101 shares in the last quarter. Quantamental Technologies LLC acquired a new stake in shares of Alkermes during the 4th quarter worth $140,000. Nordea Investment Management AB acquired a new stake in shares of Alkermes during the 3rd quarter worth $183,000. LPL Financial LLC acquired a new stake in shares of Alkermes during the 3rd quarter worth $212,000. Finally, NumerixS Investment Technologies Inc grew its holdings in shares of Alkermes by 756.9% during the 4th quarter. NumerixS Investment Technologies Inc now owns 7,712 shares of the company’s stock worth $220,000 after purchasing an additional 6,812 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.
NASDAQ:ALKS opened at $27.31 on Thursday. The stock has a market capitalization of $4.33 billion, a P/E ratio of -390.14 and a beta of 1.72. The company has a current ratio of 2.94, a quick ratio of 2.65 and a debt-to-equity ratio of 0.25. Alkermes Plc has a twelve month low of $27.09 and a twelve month high of $51.70.
Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, April 25th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.21. The business had revenue of $223.10 million for the quarter, compared to analyst estimates of $218.84 million. Alkermes had a negative return on equity of 2.08% and a negative net margin of 15.86%. Alkermes’s revenue was down .9% compared to the same quarter last year. During the same period last year, the firm posted ($0.09) earnings per share. Equities analysts predict that Alkermes Plc will post -0.37 EPS for the current fiscal year.
Several analysts have recently issued reports on ALKS shares. Cantor Fitzgerald set a $33.00 target price on Alkermes and gave the stock a “hold” rating in a report on Wednesday, January 23rd. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Alkermes in a research note on Thursday, January 10th. ValuEngine lowered Alkermes from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Citigroup lowered Alkermes from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $62.00 to $33.00 in a research note on Wednesday, May 1st. Finally, Zacks Investment Research lowered Alkermes from a “buy” rating to a “hold” rating in a research note on Tuesday, March 19th. Five equities research analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the company’s stock. Alkermes presently has an average rating of “Hold” and an average target price of $40.50.
In other Alkermes news, Director Paul J. Mitchell sold 1,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $36.64, for a total value of $36,640.00. Following the completion of the transaction, the director now directly owns 8,000 shares in the company, valued at $293,120. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Landine sold 20,000 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $32.07, for a total value of $641,400.00. Following the completion of the transaction, the senior vice president now owns 205,122 shares of the company’s stock, valued at $6,578,262.54. The disclosure for this sale can be found here. Insiders sold 157,000 shares of company stock valued at $5,218,470 over the last quarter. Corporate insiders own 4.71% of the company’s stock.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
See Also: P/E Growth (PEG)
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes Plc (NASDAQ:ALKS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.